Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART19A in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT06212154Phase 1Terminated
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of thiscart19a in autoimmune hemolytic anemia (AIHA), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Treatment-Emergent Adverse Events at 6 months and Maximum Tolerated Dose at 28 days. Started Jan 2024; status: terminated.
02
Drugs
thiscart19a
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT06212154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212154.